Výsledky vyhledávání - "Elisabeth M. Wever"

Treatment of local-regional prostate cancer detected by PSA screening: benefits and harms according to prognostic factors

Autor: Elisabeth M. Wever, Fritz H. Schröder, H.J. de Koning, Gerrit Draisma, Monique J. Roobol, Eveline A.M. Heijnsdijk, C.H. Bangma

Publikováno v: British Journal of Cancer
British Journal of Cancer, 108(10), 1971-1977. Nature Publishing Group

Background: Men with screen-detected prostate cancer can choose to undergo immediate curative treatment or enter into an expectant management programme. We quantified how the benefits and harms of immediate treatment vary according to the prognostic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0a32a504ae357a47b3eb4bac361f082
https://hdl.handle.net/1765/56355

Zobrazit plný text záznamu

To be screened or not to be screened? Modeling the consequences of PSA screening for the individual

Autor: Gerrit Draisma, H.J. de Koning, Eveline A.M. Heijnsdijk, Jonas Hugosson, Elisabeth M. Wever, Chris H. Bangma

Publikováno v: British Journal of Cancer
British Journal of Cancer, 107(5), 778-784. Nature Publishing Group

BACKGROUND: Screening with prostate-specific antigen (PSA) can reduce prostate cancer mortality, but may advance diagnosis and treatment in time and lead to overdetection and overtreatment. We estimated benefits and adverse effects of PSA screening f

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83cb9db2ba37b838f1f3a3406d591a6a
https://doi.org/10.1038/bjc.2012.317

Zobrazit plný text záznamu

Quality-of-Life Effects of Prostate-Specific Antigen Screening

Publikováno v: New England Journal of Medicine, 367(7), 595-605. Massachussetts Medical Society
New England journal of medicine, 367(7), 595-605. Massachussetts Medical Society
Asian Journal of Andrology

Background After 11 years of follow-up, the European Randomized Study of Screening for Prostate Cancer (ERSPC) reported a 29% reduction in prostate-cancer mortality among men who underwent screening for prostate-specific antigen (PSA) levels. However

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::055e65a481798a5a8891f5873f1e50e3
https://doi.org/10.1056/nejmoa1201637

Zobrazit plný text záznamu

The impact of PLCO control arm contamination on perceived PSA screening efficacy

Autor: Jeffrey Katcher, Alexander Tsodikov, Harry J. de Koning, Elisabeth M. Wever, Angela B. Mariotto, Eveline A.M. Heijnsdijk, Roman Gulati, Ruth Etzioni

Publikováno v: Cancer Causes & Control, 23(6), 827-835. Springer Netherlands

To quantify the extent to which a clinically significant prostate cancer mortality reduction due to screening could have been masked by control arm screening (contamination) in the Prostate, Lung, Colorectal, and Ovarian (PLCO) trial.We used three in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0310f069849f06faea442cc6d7cad699
https://hdl.handle.net/1765/69821

Zobrazit plný text záznamu

What If I Don't Treat My PSA-Detected Prostate Cancer? Answers from Three Natural History Models

Autor: David F. Penson, Jeffrey Katcher, Ruth Etzioni, Gerrit Draisma, Harry J. de Koning, Roman Gulati, Elisabeth M. Wever, Lurdes Y. T. Inoue, Shih Yuan Lee, Alexander Tsodikov, Eveline A.M. Heijnsdijk

Publikováno v: Cancer Epidemiology Biomarkers & Prevention, 20(5), 740-750. American Association for Cancer Research Inc.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 20(5), 740-750. AMER ASSOC CANCER RESEARCH

Background: Making an informed decision about treating a prostate cancer detected after a routine prostate-specific antigen (PSA) test requires knowledge about disease natural history, such as the chances that it would have been clinically diagnosed

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed6c0fd85f7364a737dcbf41756c73aa
https://doi.org/10.1158/1055-9965.epi-10-0718

Zobrazit plný text záznamu

How Does Early Detection by Screening Affect Disease Progression? Modeling Estimated Benefits in Prostate Cancer Screening

Autor: Elisabeth M. Wever, Gerrit Draisma, Eveline A.M. Heijnsdijk, Harry J. de Koning

Publikováno v: Medical Decision Making, 31(4), 550-558. SAGE Publishing

Background. Simulation models are essential tools for estimating benefits of cancer screening programs. Such models include a screening-effect model that represents how early detection by screening followed by treatment affects disease-specific survi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef419ccb604d183bfa9ca0b6360c849c
https://pure.eur.nl/en/publications/ab291ab2-7599-404b-bdd3-6dbccee47787

Zobrazit plný text záznamu

Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data

Autor: C.H. Bangma, L. Denis, Jonas Hugosson, Vera Nelen, Monique J. Roobol, Anssi Auvinen, Maciej Kwiatkowski, Sigrid Carlsson, A. Villers, Elisabeth M. Wever, Eveline A.M. Heijnsdijk, Fritz H. Schröder, Teuvo L.J. Tammela, Marco Zappa, T. M. de Carvalho, A. Páez, S. M. Moss, F. Recker, H.J. de Koning

Publikováno v: Journal of the National Cancer Institute, 107(1). Oxford University Press
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid

The European Randomized study of Screening for Prostate Cancer (ERSPC) has shown a disease-specific mortality reduction of prostate-specific antigen (PSA) screening for prostate cancer (1). After eleven years of follow-up, prostate cancer mortality w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3937b9231108806c98e00015cea1e45f
https://pubmed.ncbi.nlm.nih.gov/26088223

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání